Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-RI in Treatment Naive Waldenström's Macroglobulinemia
NCT03620903Phase 2Active, not recruiting
- Start
- Sep 2019
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies, Modified Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ibrutinib, bortezomib, rituximab in Waldenström's macroglobulinemia (WM). Started Sep 2019; status: active, not recruiting.
02
Drugs
ibrutinibbortezomibrituximab
03
Conditions
Waldenström's macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT03620903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03620903.